Biological therapy and the immune system in patients with chronic myeloid leukemia

International Journal of Hematology

Volumn 96, Issue 1, 2012, Pages 1-9

  Rohon, Peter ^a  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

Author keywords

Chronic myeloid leukemia; Immunomodulation; Interferon alpha; Leukemiaassociated antigens; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; BOSUTINIB; DASATINIB; IMATINIB; LEUKEMIA ANTIGEN; NILOTINIB; PEPTIDE VACCINE; PROTEIN TYROSINE KINASE INHIBITOR;

BIOLOGICAL THERAPY; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; DRUG TOLERABILITY; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; MOLECULARLY TARGETED THERAPY; REVIEW;

ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; VACCINES, SUBUNIT;

EID: 84861823658     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1116-8     Document Type: Review

References (80)

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;10:3343.
2. Druker BJ, Guilhot F, O'Brien SG. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408.
3. Hochhaus A, Baccarani M, Deininger M. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22:1200.
4. Kantarjian HM, Giles F, Gattermann N. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540.
5. Saglio G, Kim DW, Issaragrisil S, ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251-9.
6. Rix U, Hantschel O, Durnberger G. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007;110:4055.
7. Giles FJ, Cortes J, Jones D, et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood. 2007;109:500.
8. Kantarjian H, le Coutre P, Cortes J, et al. Phase I study of INNO- 406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome- positive leukemias post-imatinib resistance or intolerance. Cancer. 2010;16:2665.
9. Rousselot P, Huguet F, Rea D. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007;109:58.
10. Mustjoki S, Lundan T, Knuutila S, Porkka K. Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia. Leukemia. 2007;21:2363.
11. Rezvani K, Barrett AJ. Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Pract Res Clin Haematol. 2008;3:437.
12. Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol. 2010;85:387.
13. Barrett AJ, Savani BN. Does chemotherapy modify the immune surveillance of hematologicalmalignancies? Leukemia. 2009;23:53.
14. Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet. 2005;365:657.
15. Rojas JM, Knight K, Wang L, Clark RE. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia. 2007;21:2287.
16. van den Hove LE, Vandenberghe P, van Gool SW, Ceuppens JL, et al. Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: evidence for systemic activation of the T cell compartment. Leuk Res. 1998;22:175.
17. Rezvani K, Grube M, Brenchley JM, et al. Functional leukemiaassociated antigen-specific memory CD8? T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood. 2003;102:2892.
18. Kreutzman A, Juvonen V, Kairisto V, et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 2010;116:772.
19. Molldrem JJ, Lee PP, Kant S. Chronic myeloid leukemia shapes host immunity by a selective deletion of high-avidity leukemiaspecific T cells. J Clin Invest. 2003;111:639.
20. Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T-cells and immune tolerance. Cell. 2008;133(5):775-87.
21. Chen J, Schmitt A, Giannopoulos K. Imatinib impairs the proliferation and function of CD4? CD25? regulatory T cells in dose dependent manner. Int J Oncol. 2007;31:1133.
22. Humlova E, Klamova H, Janatkova I. Immunological profiles of patients with chronic myeloid leukemia. State before the start of treatment. Folia Biol. 2006;52:47.
23. Cathcart K, Pinilla-Ibarz J, Korontsvit T, et al. A multivalent bcrabl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood. 2004;103(3):1037.
24. Nitin J, Reuben JM, Kantarjian H, et al. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer. 2009;115(17):3924.
25. Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, et al. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses. Haematologica. 2005;90(10):1324.
26. Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med. 2007;9(14):1.
27. Greiner J, Schmitt M. Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia. Eur J Haematol. 2008;80(6):461.
28. Narita M, Masuko M, Kurasaki T, et al. WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase. Int J Med Sci. 2010;7(2):72.
29. Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008;111(2):236.
30. May RJ, Dao T, Pinilla-Ibarz J, et al. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4? and CD8? T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res. 2007;13(17):5226.
31. Schmitt M, Schmitt A, Rojewski MT. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma elicits immunologic and clinical response. Blood. 2008;111:1357.
32. Quintarelli C, Dotti G, De Angelis B, et al. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood. 2008;112:1876.
33. Hernández-Boluda JC, Bellosillo B, Vela MC, et al. Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients. Leuk Lymphoma. 2005;5:717.
34. Pinilla-Ibarz J, Shah B, Dubovsky JA. The biological basis for immunotherapy in patients with chronic myelogenous leukemia. Cancer Control. 2009;16:141.
35. Porkka K, Mustjoki S, Simonsson B. Suboptimal responses in chronic myeloid leukemia: milestones and mechanisms. Expert Rev Hematol. 2009;2:81.
36. Blake S, Hughes TP, Mayrhofer G, Lyons AB. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol. 2008;127:330.
37. Chen J, Schmitt A, Chen B. Nilotinib hampers the proliferation and function of CD8? T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med. 2008;12:2107.
38. Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a smallmolecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 2008;111:1366.
39. Weichsel R, Dix C, Wooldridge L. Profound inhibition of antigen- specific T-cell effector functions by dasatinib. Clin Cancer Res. 2008;14:2484.
40. Hayashi Y, Nakamae H, Katayama T, et al. Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib. Leuk Lymphoma. 2012; doi: 10.3109/10428194.2011.647017.
41. Aswald JM, Lipton JH, Aswald S, et al. Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia. Cytokines Cell Mol Ther. 2002;4:143.
42. Leder C, Ortler S, Seggewiss R, et al. Modulation of T-effector function by imatinib at the level of cytokine secretion. Exp Hematol. 2007;8:1266.
43. Blake S, et al. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood. 2008;111(8):4415-6.
44. Salih J, Hilpert J, Placke T, et al. Th e BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer. 2010;127:2119.
45. Kim DH, Kamel-Reid S, Chang H, et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica. 2009;94:135.
46. Mustjoki S, Ekblom M, Arstila TP. Clonal expansion of T/NKcells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23:1398.
47. Nagata Y, Ohashi K, Fukuda S, et al. Clinical features of dasatinib induced large granular lymphocytosis and pleural effusion. Int J Hematol. 2010;91:799.
48. Ravandi F. Dasatinib, an immunomodulator? Blood. 2010;116:673.
49. Powers JJ, Dubovsky JA, Epling-Burnette PK, et al. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma. 2011;52:668.
50. Melenhorst JJ, Scheinberg P, Chattopadhyay PK, et al. High avidity myeloid leukemia-associated antigen-specific CD8? T cells preferentially reside in the bone marrow. Blood. 2009;113:2238.
51. Sillaber C, Herrmann H, Bennett K. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest. 2009;39:1098.
52. Kreutzman A, Ladell K, Koechel C, et al. Expansion of highly differentiated CD8(?) T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia. 2011;25:1587.
53. Derhovanessian E, Larbi A, Pawelec G. Biomarkers of human immunosenescence: impact of Cytomegalovirus infection. Curr Opin Immunol. 2009;21:440.
54. Simonsson B, Hjorth-Hansen H, Bjerrum OW, Porkka K. Interferon alpha for treatment of chronic myeloid leukemia. Curr Drug Targets. 2011;12:420.
55. Hochhaus A, Yan XH, Willer A, et al. Expression of interferon regulatory factor (IRF) genes and response to interferon-alpha in chronic myeloid leukaemia. Leukemia. 1997;11:933.
56. Burchert A, Wolfl S, Schmidt M, et al. Interferon alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood. 2003;101:259.
57. Essers MA, Offner S, Blanco-Bose WE, et al. IFN alpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458:904.
58. Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 2001;98:3074.
59. Mahon FX, Delbrel X, Cony-Makhoul P, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol. 2002;20:214.
60. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001;6:34.
61. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202:8.
62. Chawla-Sarkar M, Lindner DJ, Liu YF, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis Int J Program Cell Death. 2003;8(3):237-49. (Pubitemid 36749609)
63. Pfeffer LM. The role of nuclear factor kappaB in the interferon response. J Interferon Cytokine Res. 2011;31:553.
64. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994;84:4064.
65. Lee MS, Kantarjian H, Talpaz M, et al. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood. 1992;79:1920.
66. Talpaz M, Kantarjian H, Kurzrock R, et al. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med. 1991;114:532.
67. Kujawski LA, Talpaz M. The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev. 2007;18:459.
68. Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363:2511.
69. Nicolini FE, Hayette S, Legros L, et al. Pegylated IFN-alpha2a combined to imatinib mesylate 600 mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600 mg daily alone. Leuk Res. 2011;35:80.
70. Palandri F, Castagnetti F, Iacobucci I, et al. The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphiapositive chronic myeloid leukemia patients in early chronic phase. Haematologica. 2010;95:1415.
71. Burchert A, Muller MC, Kostrewa P, et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol. 2010;28:1429.
72. Kreutzman A, Rohon P, Faber E, et al. Chronic myeloid leukemia patients in prolonged remission following interferon alpha monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS One. 2011;6:23022.
73. Savani BN, Mielke S, Adams S, et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia. 2007;21:2145.
74. Yong AS, Keyvanfar K, Hensel N, et al. Primitive quiescent CD34? cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood. 2009;113:875.
75. Kanodia S, Wieder E, Lu S, et al. PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. PLoS One. 2010;5:11770.
76. Rey J, Veuillen C, Vey N, et al. Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectors. Trends Mol Med. 2009;15:275.
77. Siegers GM, Felizardo TC, Mathieson AM, et al. Anti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic ph leukemia model. PLoS One. 2011;6:16700.
78. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22:633.
79. Correia MP, Costa AV, Uhrberg M, et al. IL-15 induces CD8? T cells to acquire functional NK receptors capable of modulating cytotoxicity and cytokine secretion. Immunobiology. 2011; 216:604.
80. Chen Y, Peng C, Li D, et al. Molecular and cellular bases of chronic myeloid leukemia. Protein cell. 2010;1:124.